Video

Dr. Upadhyaya on Outcomes for Children on the SJYC07 Trial

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

One of the most important goals on this trial, Upadhyaya says, was seeing if these children can be safely radiated starting at 1 year of age. Based on the trial results so far, Upadhyaya reports that it is possible. Children as young as 1-year-old with ependymomas can be safely treated with radiation to improve outcomes, he says.

The second most important consideration, Upadhyaya says, was whether radiation-deferring strategies could be used until a child’s brain matured to a point that radiation would be safe to use. Surgery and chemotherapy have been used as a bridge to get these children to 1 year of age, where they can then be treated with radiation.

Additionally, the presence of 3 molecularly distinct groups of ependymomas have been validated in this subgroup of patients, PF-A, ST-RELA, and ST-YAP. Upadhyaya notes that while RELA-fused ependymomas are the more aggressive cases, these patients had better-than-expected results on the SJYC07 trial.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD